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Abstract
The subepidermal immunobullous diseases are a group of autoimmune blistering disorders of the
skin and mucous membranes that share the common features of autoantibody deposition and
blister formation at the dermal-epidermal junction or basement membrane. This group includes
bullous pemphigoid, linear IgA disease, dermatitis herpetiformis, and epidermolysis bullosa
acquisita, among others. Although these disorders share some common features, each disease is
unique in its clinical presentation, histopathology, and immunofluorescence patterns, which allows
for accurate diagnosis and disease-specific treatment strategy. Treatment of these disorders is
complex and requires expert knowledge of disease pathogenesis. We review common treatment
approaches for each of these disorders.
Introduction
The group of subepidermal immunobullous diseases encompasses many specific disorders
including bullous pemphigoid (BP), linear IgA disease (LAD), dermatitis herpetiformis
(DH), and epidermolysis bullosa acquisita (EBA), among others. As each of these diseases
is characterized by an autoimmune response directed against skin adhesion molecules, there
is a common thread to treatment approaches; however, each disease has clinical and
immunological subtleties that further refine treatment strategy. As with many rare disorders,
a standard approach to treatment is limited by lack of large randomized controlled trials.
This review focuses on treatment of BP, LAD, DH, and EBA.
Bullous pemphigoid
BP is an autoimmune disorder characterized by autoan-tibodies directed against BP180
(collagen type XVII, BPAg2) and less often BP230 (BPAg1).1–3 Recent studies have
revealed that eventual blister formation is the result of multiple complex interactions
involving autoantibody binding and complement activation leading to activation of cells
such as neutrophils, eosinophils, and mast cells.4–7 First-line treatments are typically general
immunosuppressives, but newer agents that target these distinct steps in disease
pathogenesis are beginning to emerge. Disease presentation may be limited to a localized
form or may present with a widespread, generalized blistering eruption. As a result,
treatment of BP depends greatly on the extent of disease as well as patient comorbidities.
Interventions for the treatment of BP was the recent subject of a Cochrane review update,
which provides a detailed summary of the most evidence-based approach to therapy.8
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Potent topical corticosteroids alone are often successful in treating limited or localized
BP.9–12 More recent studies have suggested that high-potency topical steroids are also useful
in treating more severe disease. A 1992 report revealed that high doses of superpotent
topical corticosteroids at 40 g/d were more effective and increased survival in patients with
moderate and severe BP compared with oral prednisone at 1 mg/kg/d in a large, controlled
trial of 34 patients.13 In this study, patients were treated with clobetasol propionate cream at
40 g/d with a slow taper over 12 months. Several patients experienced local and systemic
complications, possibly because of the high dose and length of treatment. To this end, a
follow-up multicenter randomized controlled trial of 312 patients was designed to test
whether a milder regimen of topical corticosteroids could achieve the same level of disease
control with decreased side effects. Results showed that the mild regimen of topical
corticosteroids (clobetasol propionate cream 10 to 30 g/d with a 4-month taper) was equally
as effective as the previous dosing regimen.14 In addition, for patients with moderate
disease, those treated with the mild regimen showed a twofold decrease in the risk of death
or life-threatening adverse events compared with the standard dosing. Many have argued
that the efficacy of high-potency topical steroids is simply a result of systemic absorption.
For example, a 30-g/d application of clobetasol propionate cream results in absorption of a
dose of steroid equivalent to 45 mg/d of oral prednisone.15 Such widespread topical therapy
can be expensive and difficult to apply, particularly for the elderly, which often proves
prohibitive in many patients. In our experience, the use of high-potency topical steroids has
been useful in controlling the localized forms of BP. It appears that the use of high-potency
topical steroids to treat BP patients with widespread skin disease is not a common practice
among US dermatologists treating these patients (Luis A. Diaz, unpublished observation,
2011).
Although not a corticosteroid, tacrolimus is the only other topical agent reported to be useful
in treating BP. These reports, however, are limited and involve a small number of cases of
localized BP.10,16–19
Systemic corticosteroids
More extensive disease is usually treated with oral prednisone, which is the mainstay of
therapy.10,20,21 Although none of the randomized, controlled trials performed to date has
included a placebo arm, there are 2 studies evaluating systemic steroids as single-agent
treatment.22,23 Varying doses of prednisolone 0.75 mg/ kg/d (n = 24) versus 1.25 mg/kg/d (n
= 22) were compared in a multicenter randomized trial with no significant difference in new
blister formation or healing of existing lesions at days 21 and 51.23 In the second study, 2
formulations of oral steroids were compared: prednisolone 1.16 mg/kg/d (n = 29) versus
methylprednisolone 1.17 mg/ kg/d (n = 28).22 At day 10 of treatment, both groups showed a
large reduction in the number of bullous lesions, but there was no statistically significant
difference between the groups. The authors reported a significant decrease in the intensity of
pruritus that was more pronounced in the methylprednisolone group (P < .05), but no
difference in the regression of erythema between the 2 treatment groups.22 Finally, high-
dose “pulse” therapy with intravenous methylprednisolone also has been reported to be
effective in rapidly controlling active blister formation in hospitalized BP patients, although
the study was limited by lack of a control group and small sample size (n = 8).24
Although the optimal dosing and formulation of systemic corticosteroid therapy remains
unclear, the complications of such therapy (including osteoporosis, diabetes, hypertension,
cataracts, glaucoma, and systemic infection) may be especially severe, particularly in the
elderly25; therefore, it is important to minimize the total dose and duration of therapy with
oral glucocorticoids. In our experience, as well as others,26 a starting dose of prednisone of
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0.75 to 1.00 mg/ kg/d or even less may be adequate to achieve disease control. Once the
development of blisters has been arrested and the erythema has subsided, a careful tapering
of the prednisone is recommended. This objective is usually reached by the end of second
week of therapy, when the patient is already receiving an adjuvant immunosuppressive drug.
A weekly lowering of 5 mg to reach 30 mg is commonly used. Tapering the steroids below
30 mg should be done gradually and slowly, following an alternate day scheme. In our
experience, decreasing prednisone by 2.5 mg every week on alternate days is very rewarding
and prevents relapses. Tapering of the dose must be done according to the clinical response
of the patients. The addition of steroid-sparing agents, such as those listed in the following
sections, may facilitate tapering of systemic corticosteroids and help to minimize
corticosteroid-associated adverse events.
Azathioprine
Azathioprine is a prodrug that is converted in non-enzymatic fashion to 6-mercaptopurine
(6-MP). 6-MP is subsequently converted into 6-tioguanine nucleotides, which function as
nucleotide analogs and lead to eventual lymphocyte impairment. When added to prednisone,
azathioprine may allow for a decrease in the dosing of corticosteroids. A pioneer study in
197827 showed that although there was no difference in level of disease control at 3 years
between patients on prednisone plus azathioprine 2.5 mg/kg/d (n = 12) and those on
prednisone alone (n = 13), the addition of azathioprine allowed for a 45% reduction in the
amount of prednisone necessary to control disease during the 3-year treatment period (P < .
01).
A subsequent study also failed to show any difference in disease control (defined as no new
blister formation) at the 28-day and 6-month follow-up when azathioprine was added to
prednisone treatment (prednisone alone 1 mg/kg/d, n = 31; prednisone 1 mg/kg/d plus
azathioprine 100 to 150 mg/d, n = 36)28; however, the steroid-sparing ability of adding
azathioprine was not reported as an outcome measure.
In both studies, there were no statistically significant differences in mortality between
treatment groups.
The most significant adverse effect noted with the addition of azathioprine in these studies
was a reduction in the white cell count. Myelosuppression is a known potential side effect of
azathioprine. Risk of myelosuppresion while on azathioprine may be related to thiopurine
methyltransferase (TPMT) activity, an enzyme that converts 6-MP into inactive metabolites.
Patients with low (or absent) TPMT activity will have a compensatory increase in
conversion of 6-MP to active metabolites, leading to increased susceptibility to treatment-
related myelosuppression.29,30 Preemptive testing of TPMT activity levels may allow for a
more tailored dosing, such that patients with a low TPMT activity level are started on a
lower initial dosing, thereby minimizing their risk of myelosuppression.30,31 In addition,
patients with a high TPMT activity level may require higher doses to see any appreciable
effect from the addition of azathioprine.30 As TPMT testing was not available at the time the
studies on azathioprine described previously were conducted, suboptimal dosing may
account for the lack of apparent effect. In our practice, we typically start patients at a dose of
50 mg/d and slowly titrate the dosing based on TPMT activity and weight.
Adverse effects other than myelosuppression include cytopenia, hepatitis, pancreatitis, and
an increased risk of infection. Careful monitoring of patients on azathioprine is necessary to
detect signs or symptoms that may indicate toxicity. Finally, there is the potential for serious
drug interactions when azathioprine is given to patients taking certain medications.
Allopurinol inhibits xanthine oxidase, thereby shunting 6-MP toward conversion to active
metabolites and, thus, increasing the potential for myelosuppression.32 Azathioprine has
Culton and Diaz Page 3













been implicated in inducing warfarin resistance. As a result, warfarin doses may need to be
increased when azathioprine is added.33 A complete review of all concurrent medications is
critical to avoiding serious drug interactions.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, which
controls the rate of synthesis of guanine monophosphate, in turn impairing purine synthesis
and altering the function of proliferating T and B cells. MMF has been used to control
transplant rejection. The use of MMF in BP has predominantly been limited to case reports
and small case series with noted efficacy.34–37 Some of these reports have even shown
successful control of disease using MMF as monotherapy in select patients,35,36 although it
is typically added to systemic corticosteroids for potential steroid-sparing effect. More
recently, a multicenter, randomized trial compared MMF 1 g twice daily (n = 35) and
azathioprine 2 mg/kg/d (n = 38) as adjuvant therapy to oral methylprednisolone 0.5 mg/kg/d
in 73 BP patients.38 These medications showed similar efficacy in terms of time to complete
remission (defined as complete reepithelialization of all lesions), cumulative dose of
systemic steroids, and duration of remission. Although the efficacy of the 2 drugs was
similar, the azathioprine plus methylprednisolone group had significantly higher toxicity
grades for aspartate aminotransferase, alanine aminotransferase, and -glutamyltransferase,
when compared with the MMF plus methylprednisolone group, all of which reached
statistical significance.38 One important point to note is that TPMT levels were not checked
in the azathioprine group before treatment. No methylprednisolone-only arm was included
in this study.
Side effects of MMF include risk of systemic infection, cytopenias, and more commonly,
gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and anal
tenderness.39 Hepatotoxicity may also occur. Some drugs may decrease the absorption of
MMF, including cholestyramine (enterohepatic circulation) and magnesium or aluminum
hydroxides. Acyclovir and ganciclovir can increase MMF levels by competing for renal
tubular excretion.39
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard alkylating agent that is metabolized in the liver to
active forms of the drug. These active metabolites are known to attach alkyl groups to
guanine and crosslink DNA, leading to cell death. Cyclophosphamide has been used to treat
patients with a variety of cancers and autoimmune diseases including pemphigus vulgaris
and BP. Although cyclophosphamide is often used to treat ocular cicatricial pemphigoid,
several case reports have suggested that cyclophosphamide may also be useful in cases of
severe or refractory BP when given in either oral daily (1–5 mg/kg/d) or pulse intravenous
dosing.40,41 No large or randomized trials have been performed using this medication.
Side effects can be severe and include infection, nausea, vomiting, leucopenia,
thrombocytopenia, increased risk of lymphoma, and hemorrhagic cystitis, which occurs in
40% of patients.39 Hemorrhagic cystitis is attributable to the toxic metabolite acrolein and is
associated with an increased risk of transitional cell carcinoma of the bladder. Mesna
(sodium 2-mercaptoethanesulfonate) is a scavenging agent that binds acrolein and may be
used to prevent hemorrhagic cystitis. Increased fluid intake and frequent voiding are also
recommended to decrease bladder toxicity.39
Methotrexate
Methotrexate (MTX) inhibits the reduction of folic acid by the enzyme dehydrofolate
reductase, leading to depletion of nucleotide precursors, which in turn impairs the synthesis
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of DNA, RNA, and proteins. As an antimetabolite, immunosuppressive agent, and anti-
inflammatory drug, MTX is used in the treatment of cancer and autoimmune disease.
Although no randomized, controlled trials have been performed, there are several reports of
low-dose weekly MTX being effective in combination with oral or topical corticosteroids.
There is a report of a series of 11 consecutive patients with BP who were not responding to
potent topical steroids.42 MTX was started at 5 mg/wk and increased by 2.5 mg/wk to a
maximum of 12.5 mg/wk. All patients responded with a decrease in disease activity and in 8
of 11 patients, the disease was controlled with minimal doses of MTX (5.0 to 7.5 mg/wk),
whereas 3 of 11 required higher doses (10–12.5 mg/wk).42 Other studies have corroborated
these findings.43 Similar results were obtained when comparable doses of MTX were
administered via intramuscular injection.44 A recent meta-analysis included results of 6
studies of MTX used in a total of 79 BP patients.45 Overall, 94% of BP patients showed
clinical improvement on MTX. Finally, a single-center retrospective analysis of 98 patients
on MTX for BP showed a decrease in the time to complete remission compared with those
on prednisone alone.46 Many of these patients were controlled with MTX as monotherapy.46
Although there have been no randomized, controlled trials of MTX in BP, the above
findings are certainly promising and warrant further investigation.
Side effects of MTX are well known and include pancytopenia and hepatotoxicity.39,43,46
Patients with renal disease, those on nonsteroidal anti-inflammatories, and those with no
folic acid supplementation are at increased risk of pancytopenia. Folinic acid (Leucovorin)
can be given as a rescue for myelosuppression if needed. Hepatic fibrosis and cirrhosis can
occur with chronic administration. Patients with liver compromise (hepatitis B or C, alcohol
use, diabetes, and obesity) are at increased risk of liver complications.39,43,46
Photosensitivity and radiation recall are known complications of MTX therapy. The most
common side effects include fatigue, nausea, and vomiting, which can often be overcome
with folic acid supplementation.39,43,46 MTX is known to have numerous drug interactions.
Nonsteroidal anti-inflammatories, salicylates, and sulfonamides (trimethoprim-
sulfamethoxazole, dapsone) displace MTX from plasma proteins and decrease renal
excretion, thereby increasing MTX levels. Chloramphenicol, phenothiazines, phenytoin, and
tetracyclines also increase MTX levels by displacement from plasma proteins. It is prudent
to monitor liver function and complete blood counts in patients on this medication. Liver
ultrasound and/or biopsy may be considered following 1.5 g of cumulative dose.39,43,46
Dapsone
Dapsone is a drug with chemotherapeutic and anti-infectious properties. Its utility in the
treatment of skin disorders, particularly those involving neutrophil dysfunction, is well
known.47–49 A recent meta-analysis reviewed data from 6 studies with a total of 170 BP
patients.50 Dapsone was used alone or in combination with corticosteroids and/or other
immunosuppressive therapy. Altogether, 81% of patients showed clinical improvement on
dapsone at doses ranging from 50 to 300 mg/d.50 Dapsone was more useful in combination
with steroids or other immunosuppressives than as monotherapy. Hemolysis was the most
common adverse event and was dose related in these studies.
Other potential side effects from dapsone include methemoglobinemia, hemolysis,
idiopathic agranulocytosis, and anemia. Methemoglobinemia occurs in almost all patients
but is clinically significant when methemoglobin levels reach 30% or higher.51 Symptoms
of dyspnea, nausea, and tachycardia may be early signs of toxicity. Hemolysis is also a
predictable side effect in patients on dapsone.52 It occurs in a dose-dependent manner and is
reversible to some extent. Glucose-6-phosphate dehydrogenase level should be checked
before starting dapsone, as deficiency of this enzyme increases the risk of hemolysis.
Addition of cimetidine may reduce the anemia associated with dapsone.53 A more rare and
serious side effect is dapsone hypersensitivity syndrome, which presents with fever,
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lymphadenopathy, and dermatitis.54 Peripheral neuropathy involving motor neurons of
extremities can also complicate treatment with dapsone at doses greater than 100 mg/d. It is
typically reversible within 1 year of discontinuation of dapsone.53
Antimicrobials
Reports have described successful treatment of some BP patients with tetracycline and
nicotinamide or variations on this theme, such as erythromycin and nicotinamide or
tetracycline alone.55–57 The authors have not had success with this treatment.
Plasmapheresis
As BP is mediated in large part by autoantibodies, several therapies are aimed at their
elimination. Plasmapheresis (and plasma exchange) involves removal of large amounts of
patient plasma over the course of several days and is typically performed during a
hospitalization, given the risk for fluid overload during the fluid/protein replacement phase.
Early studies have shown that the addition of plasma exchange to prednisolone reduced the
amount of prednisolone (both daily and cumulative dose) necessary to achieve disease
control (defined as lack of new blister formation and resolution of old lesions) at 1-month
follow-up.58 The steroid-sparing effect of plasmapheresis was corroborated in 2 studies59,60;
however, a third study failed to show any benefit when plasma exchange was added to
prednisolone.28 Given its cost and associated risk, plasmapheresis is best reserved for
patients with recalcitrant disease that does not respond to more standard therapy.
Intravenous immunoglobulin
Intravenous immunoglobulin (IVIg) has been used to reduce circulating autoantibodies in
many autoimmune disorders, including pemphigus.61 Although the exact mechanism of
action is not completely clear, IVIg may act by increasing antibody catabolism.62 Use of
IVIg in patients with BP has been limited to case reports and series with conflicting
results63–66; however, a recent meta-analysis of 17 cases showed that 70% of patients
experienced a beneficial clinical response to IVIg.67 The largest case series to date describes
15 patients with recurrent BP who experienced significant side effects from more
conventional therapy.68 In these patients, IVIg at a dose of 2 g/kg/cycle resulted in clinical
remission in all patients and showed a steroid-sparing effect. There were no serious side
effects. Potential side effects of IVIg are numerous and include anaphylaxis, infection,
thrombosis, and renal failure.69 In addition, this therapy is quite expensive. These factors
should limit its use to patients with severe, refractory disease or severe complications on
conventional therapy.
Rituximab
Rituximab is a monoclonal antibody directed against the B lymphocyte cell-surface protein
CD20. Rituximab is becoming increasingly used for refractory pemphigus; however, use in
BP is limited.70 Initial reports describe complete remission in 2 cases of BP in patients
receiving rituximab for chronic lymphocytic leukemia.71 Following these initial
observations, an increasing number of case reports emerged reporting mixed results when
rituximab is used in BP.72–77 A recent summary of the literature revealed that 7 of 9 BP
patients treated with rituximab showed complete remission, whereas 2 of 2 patients showed
at least partial remission. To these existing reports, an additional 5 cases were added, in
which 3 patients experienced complete remission, 1 partial remission, and 1 patient died.73
Omalizumab
As the role of IgE in the pathogenesis of BP emerges, focus has turned to promising new
drugs, such as omalizumab, a monoclonal antibody that prevents binding of IgE to the high-
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affinity FcεRI. There is a single case of steroid-unresponsive BP with clinical improvement
following 16 weeks of omalizumab treatment.78 Although the patient experienced clinical
improvement within 1 week of her first dose, she did have residual disease at the end of the
16-week trial. An open-label, randomized trial of omalizumab for BP is currently under
way, and highlights how advances in understanding the pathogenesis of BP may translate
directly to new therapeutic targets.
Linear IgA disease
LAD is a subepidermal blistering disorder characterized clinically by tense bullae, often in a
“crown of jewels” configuration.79 Histologically, LAD shows a subepidermal split with
linear IgA staining on direct immunofluorescence. Although clinical trials are lacking, the
treatment of choice is dapsone with or without systemic corticosteroids.80,81 For a review of
dosing, side effects, and monitoring of dapsone, please refer to the previous section, which
describes the use of dapsone in the treatment of BP. Other reported treatments include
colchicine,82–86 trimethoprin-sulfamethoxazole,87 tacrolimus ointment,88 mycophenolate,89
immunoadsorption,90 and IVIg.91,92 Obviously, in drug-induced cases, the offending
medication should be discontinued.
Treatment protocols used by the authors for BP and LAD patients
The aim of the therapy is to arrest the cutaneous inflammatory syndrome triggered by the
autoimmune process mediated by autoantibodies against the hemidesmosomal BP180
antigen.
Patients with localized disease
For patients with localized disease, treatment with high-potency topical steroids (clobetasol)
and wet dressings with physiologic saline are preferred.
Patients with widespread disease
For patients with widespread disease, treatment with systemic steroids (prednisone, 60 to 80
mg/d) along with a steroid-sparing agent is preferred. We start with azathioprine or MTX in
a large number of patients. The weekly doses of MTX may be effective and very appealing
to some patients. Other patients may respond well to mycophenolate mofetyl using doses
stated previously. In patients with contraindications to these drugs, dapsone or
cyclophosphamide may be used. Only in rare patients have we used IVIg or plasmapheresis.
Slow tapering of the steroids is crucial in preventing relapses.
Dermatitis herpetiformis
DH is a cutaneous manifestation of gluten sensitivity.93 Clinically, it is characterized by
small blisters over extensor surfaces and histologically by collections of neutrophils in the
dermal papillae with subepidermal blister formation. Immunofluorescence findings of
granular IgA deposits in the dermal papillae are confirmatory. The first-line medical
treatment is dapsone, which often leads to clinical improvement within days of starting the
medication.94–97 Dapsone should be started at 25 to 50 mg/d and slowly increased to 100 to
200 mg/d based on clinical response and medication tolerance. Monitoring for potential side
effects is critical given the risk of hemolytic anemia, methemoglobinemia, neuropathy, and
hypersensitivity (discussed in more detail previously in the section describing the use of
dapsone in the treatment of BP). Sulfasalazine and sulfamethoxypyridazine can be useful in
patients who cannot tolerate dapsone or when dapsone is ineffective98,99; however, the
mainstay of therapy is initiation of a gluten-free diet, as this reduces the need for medication,
resolves underlying enteropathy, and reduces the risk of lymphoma in these patients.100
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Patients should be referred to a dietician for guidance on adhering to a gluten-free diet, as
many food ingredients contain gluten. There are also published lists of foods that contain
gluten that may be helpful to patients.101
Epidermolysis bullosa acquisita
EBA is an acquired blistering disorder with autoantibodies predominantly against collagen
VII. Noninflammatory blisters typically occur at sites of trauma, although the clinical
presentation can be varied with more widespread inflammatory blisters in some patients.
The areas heal with scarring and milia.102 Histologic study shows subepidermal blister
formation and direct immunofluorescence shows linear IgG along the basement membrane
zone. No randomized, controlled trials have been performed to date, but several case reports
and series have been published.103 There is no clear first-line treatment for EBA, as all
therapies tend to be only partially effective as reported in a summary of the literature.104
Colchicine has been reported to be effective in some patients at high doses, although side
effects, such as diarrhea, often limit dose escalation and not all patients show
improvement.105–107 There are several case reports of IVIg improving blister formation in
EBA alone or in combination with other agents.65,104,108 Other immunomodulatory agents
(cyclosporine, dapsone, azathioprine) have been effective in reducing blister formation and
corticosteroid dose some patients.104,109–111 Systemic steroids, which are useful in so many
autoimmune bullous disorders, do not appear to be as effective in EBA, particularly when
used as monotherapy in the noninflammatory immunobullous form of EBA.104,110,112
Conclusions
Treatment of subepidermal immunobullous disorders is complex and requires knowledge of
the clinical, histological, and immunological features of each particular disease. As most
medications used to treat these disorders carry a high risk of side effects, any treatment plan
should be initiated only after consideration of patient comorbidities, concurrent medications,
extent of disease, and impact of the disease on quality of life. Treatment changes should be
guided by patient response, tolerance of medication, and, occasionally, immunological
parameters. Close follow-up and monitoring for medication side effects is critical for
successful treatment of these complex disorders.
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